ADBIC
AZN icon

A.D. Beadell Investment Counsel’s AstraZeneca AZN Stock Holding History

A.D. Beadell Investment Counsel’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Hold
6,975
– – 0.85% 41
2026
Q1 		$1.38M Sell
6,975
-5
-0.1% -$964 0.88% 41
2025
Q4 		$1.28K Hold
6,980
– – 0.83% 42
2025
Q3 		$1.07M Hold
6,980
– – 0.73% 49
2025
Q2 		$975K Hold
6,980
– – 0.74% 48
2025
Q1 		$1.03M Buy
6,980
+287
+4% +$41.5K 0.85% 43
2024
Q4 		$876K Buy
+6,693
New +$937K 0.71% 50

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

A.D. Beadell Investment Counsel's AZN Position: Q2 2026 in Review

A.D. Beadell Investment Counsel held its AstraZeneca (AZN) position steady in Q2 2026 at 6,975 shares worth $1.32M. The position accounts for 0.85% of the portfolio, ranked #41.

A.D. Beadell Investment Counsel first reported a position in AZN in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.38M in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • A.D. Beadell Investment Counsel held 6,975 shares of AstraZeneca worth $1.32M as of Q2 2026.
  • A.D. Beadell Investment Counsel left its AstraZeneca share count unchanged in Q2 2026.
  • AstraZeneca made up 0.85% of A.D. Beadell Investment Counsel's portfolio in Q2 2026, its #41 holding.
  • A.D. Beadell Investment Counsel first reported a position in AstraZeneca in Q4 2024 and has held it in 7 quarters since.
  • A.D. Beadell Investment Counsel's AstraZeneca position peaked at $1.38M in Q1 2026.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on A.D. Beadell Investment Counsel's 13F filing for Q2 2026, filed 15 Jul 2026.